Evidence map›Paper›PMID 33440869›Full record

ReviewInternational journal of molecular sciences2021

Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.

Yammy Yung, Emily Lee, Hiu-Tung Chu, Pui-Kwan Yip, Harinder Gill

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. The molecular management of classic myeloproliferative neoplasm.Journal of the Egyptian National Cancer Institute · 2025
    Review
  4. Zinc oxide fabricated by rutin as potent anti-leukemia nanostructure.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Yammy YungDivision of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Emily LeeDivision of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Hiu-Tung ChuDivision of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Pui-Kwan YipDivision of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Harinder GillDivision of Haematology, Medical Oncology and Haemopoietic Stem Cell transplantation, Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.ORCID 0000-0002-9551-4893
University of Hong Kong · HK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloproliferative neoplasms (MPNs) are unique hematopoietic stem cell disorders sharing mutations that constitutively activate the signal-transduction pathways involved in haematopoiesis. They are characterized by stem cell-derived clonal myeloproliferation. The key MPNs comprise chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). CML is defined by the presence of the Philadelphia (Ph) chromosome and

Indexed as

Disease SusceptibilityAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsAutophagyBiomarkers, TumorCell SurvivalCell Transformation, NeoplasticCombined Modality TherapyGenetic Predisposition to DiseaseHematopoietic Stem CellsHumansLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMolecular Targeted TherapyMyeloproliferative DisordersNeoplastic Stem CellsPhiladelphia ChromosomeAntineoplastic AgentsBiomarkers, Tumorchronic myeloid leukemiamyeloproliferative neoplasmstem cellstargeted therapy

Identifiers

PMID33440869
PMCPMC7827471
OpenAlexW3118753579

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.